KR950016730A - 폐경기 후 증후군과 관련한 혈관 운동 증상 및 수반되는 심리학적 장애의 억제 방법 - Google Patents
폐경기 후 증후군과 관련한 혈관 운동 증상 및 수반되는 심리학적 장애의 억제 방법 Download PDFInfo
- Publication number
- KR950016730A KR950016730A KR1019940034921A KR19940034921A KR950016730A KR 950016730 A KR950016730 A KR 950016730A KR 1019940034921 A KR1019940034921 A KR 1019940034921A KR 19940034921 A KR19940034921 A KR 19940034921A KR 950016730 A KR950016730 A KR 950016730A
- Authority
- KR
- South Korea
- Prior art keywords
- disorders associated
- suppressing
- methods
- compound
- psychological disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Abstract
하기 일반식( I )을 갖는 화합물 또는 그의 약학적으로 허용가능한 염 또는 용매화물의 효과량을 폐경기후 증후군과 관련한 혈관 운동 증상 및 수반되는 심리학적 장애의 치료를 필요로 하는 여성에게 투여함을 포함하는, 상기 증상 및 장애를 억제하는 방법:
상기식에서
R1및 R3는 독립적으로 수소, -CH3,(여기에서, Ar은 임의로 치환된 페닐이다)이고; R2는 피롤리디노, 헥사메틸렌이미노 및 피페리디노로 이루어진 그룹중에서 선택된다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (4)
- 폐경기후 증후군과 관련한 혈관 운동 중상 및 수반되는 심리학적 장애를 억제하는데 유용한 하기일반식( I )의 화합물 또는 그의 약학적으로 허용가능한 염 또는 용매화물:상기식에서,R1및 R3는 독립적으로 수소, -CH3,(여기에서, Ar은 임의로 치환된 페닐이다)이고; R2는 피롤리디노, 헥사메틸렌이미노 및 피페리디노로 이루어진 그룹중에서 선택된다.
- 제1항에 있어서, 하이드로클로라이드 염 형태인 화합물.
- 제1항에 있어서, 예방적으로 투여하는 화합물.
- 제1항에 있어서, 하기 구조식 또는 그의 하이드로클로라이드 염인 화합물:※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/173,502 | 1993-12-21 | ||
US08/173,502 US5534526A (en) | 1993-12-21 | 1993-12-21 | Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
KR950016730A true KR950016730A (ko) | 1995-07-20 |
Family
ID=22632322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019940034921A KR950016730A (ko) | 1993-12-21 | 1994-12-19 | 폐경기 후 증후군과 관련한 혈관 운동 증상 및 수반되는 심리학적 장애의 억제 방법 |
Country Status (15)
Country | Link |
---|---|
US (1) | US5534526A (ko) |
EP (1) | EP0659415A3 (ko) |
JP (1) | JPH07196500A (ko) |
KR (1) | KR950016730A (ko) |
CN (1) | CN1108093A (ko) |
AU (1) | AU691844B2 (ko) |
CA (1) | CA2138499A1 (ko) |
CZ (1) | CZ320994A3 (ko) |
HU (1) | HUT71478A (ko) |
IL (1) | IL112038A0 (ko) |
NO (1) | NO944934L (ko) |
NZ (1) | NZ270168A (ko) |
PH (1) | PH31327A (ko) |
RU (1) | RU94045278A (ko) |
ZA (1) | ZA9410093B (ko) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6417198B1 (en) | 1993-12-21 | 2002-07-09 | Eli Lilly And Company | Methods of inhibiting CNS problems in post-menopausal women |
US5596106A (en) * | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
US5512296A (en) * | 1994-08-22 | 1996-04-30 | Eli Lilly And Company | Methods for inhibiting neuronal damage |
TW442286B (en) * | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
US6110942A (en) * | 1996-06-17 | 2000-08-29 | Eli Lilly And Company | Method for minimizing the uterotrophic effect of droloxifene |
ZA982877B (en) * | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment of central nervous system disorders with selective estrogen receptor modulators. |
US6117911A (en) * | 1997-04-11 | 2000-09-12 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
US6008232A (en) * | 1997-08-20 | 1999-12-28 | Eli Lilly And Company | Methods for preventing headaches |
US6096781A (en) | 1997-11-14 | 2000-08-01 | Eli Lilly And Company | 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome |
AU3306399A (en) * | 1998-03-02 | 1999-09-20 | Eli Lilly And Company | Fluoxetine hydrochloride for decreasing hot flashes |
TR200003704T2 (tr) | 1998-06-16 | 2001-06-21 | Eli Lilly And Company | Asetilkolin düzeylerini arttırma |
US6288108B1 (en) | 1998-06-16 | 2001-09-11 | Eli Lilly And Company | Methods for increasing levels of acetylcholine |
US6258826B1 (en) | 1998-10-13 | 2001-07-10 | Eli Lilly And Company | Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome |
PT1175433E (pt) | 1999-05-04 | 2005-11-30 | Strakan Int Ltd | Glicosidos androgenos e sua actividade androgenica |
JP2006522146A (ja) * | 2003-03-31 | 2006-09-28 | ゼノポート,インコーポレイティド | Gaba類似体のプロドラッグを使用するのぼせの治療または予防 |
CA2731827C (en) | 2008-07-22 | 2017-11-07 | Menogenix, Inc. | Compositions and methods for treating symptoms associated with menopause, hormonal variations and arthritis |
US9151289B2 (en) | 2008-08-21 | 2015-10-06 | Cummins Inc. | Fuel pump |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE637389A (ko) * | 1962-09-13 | |||
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
US4729999A (en) * | 1984-10-12 | 1988-03-08 | Bcm Technologies | Antiestrogen therapy for symptoms of estrogen deficiency |
US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
US5391557A (en) * | 1993-10-15 | 1995-02-21 | Eli Lilly And Company | Methods for the treatment of peri-menopausal syndrome |
-
1993
- 1993-12-21 US US08/173,502 patent/US5534526A/en not_active Expired - Fee Related
-
1994
- 1994-12-19 EP EP94309473A patent/EP0659415A3/en not_active Withdrawn
- 1994-12-19 NO NO944934A patent/NO944934L/no unknown
- 1994-12-19 RU RU94045278/14A patent/RU94045278A/ru unknown
- 1994-12-19 ZA ZA9410093A patent/ZA9410093B/xx unknown
- 1994-12-19 CA CA002138499A patent/CA2138499A1/en not_active Abandoned
- 1994-12-19 HU HU9403662A patent/HUT71478A/hu unknown
- 1994-12-19 IL IL11203894A patent/IL112038A0/xx unknown
- 1994-12-19 JP JP6314541A patent/JPH07196500A/ja active Pending
- 1994-12-19 NZ NZ270168A patent/NZ270168A/en unknown
- 1994-12-19 CN CN94119740A patent/CN1108093A/zh active Pending
- 1994-12-19 CZ CZ943209A patent/CZ320994A3/cs unknown
- 1994-12-19 AU AU81548/94A patent/AU691844B2/en not_active Ceased
- 1994-12-19 KR KR1019940034921A patent/KR950016730A/ko not_active Application Discontinuation
- 1994-12-19 PH PH49586A patent/PH31327A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN1108093A (zh) | 1995-09-13 |
EP0659415A3 (en) | 1995-10-11 |
US5534526A (en) | 1996-07-09 |
RU94045278A (ru) | 1996-11-10 |
AU691844B2 (en) | 1998-05-28 |
CA2138499A1 (en) | 1995-06-22 |
NO944934L (no) | 1995-06-22 |
AU8154894A (en) | 1995-06-29 |
CZ320994A3 (en) | 1995-08-16 |
HU9403662D0 (en) | 1995-02-28 |
IL112038A0 (en) | 1995-03-15 |
ZA9410093B (en) | 1996-06-19 |
EP0659415A2 (en) | 1995-06-28 |
NO944934D0 (no) | 1994-12-19 |
HUT71478A (en) | 1995-11-28 |
NZ270168A (en) | 1997-07-27 |
JPH07196500A (ja) | 1995-08-01 |
PH31327A (en) | 1998-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR950016730A (ko) | 폐경기 후 증후군과 관련한 혈관 운동 증상 및 수반되는 심리학적 장애의 억제 방법 | |
KR950010893A (ko) | 자궁내막증 억제 방법 | |
KR950010890A (ko) | 폐경기 증후군의 치료방법 | |
KR950016744A (ko) | 트롬빈을 저해하는 방법 | |
KR950010892A (ko) | 자궁 섬유증 억제 방법 | |
KR950016746A (ko) | 비-펩티드 타키키닌 수용체 길항물질 | |
KR950016732A (ko) | 피부 및 질의 위축 억제방법 | |
KR950016723A (ko) | 자가면역 질병의 억제 방법 | |
KR950016725A (ko) | 폐 고혈압성 질병을 억제하는 방법 | |
KR950016745A (ko) | 생리증상의 치료방법 및 이를 위한 조성물 | |
KR970706818A (ko) | 뉴로펩티드 y와 관련된 상태의 억제 방법(methods of inhibiting conditions associated with neuropeptide) | |
KR950016731A (ko) | 지루 및 좌창의 억제 방법 | |
KR950010888A (ko) | 평활근세포 증식 및 재발협착증을 억제하는 방법 | |
KR950016726A (ko) | 기능부전성 자궁 출혈을 억제하는 방법 | |
RU97108050A (ru) | Способ ингибирования состояний, связанных с нейропептидом y | |
KR950010889A (ko) | 혈관형성 및 혈관형성성 질병을 억제하는 방법 | |
KR950010887A (ko) | 연골 퇴화 억제 방법 | |
KR950010891A (ko) | 내성 종양을 치료하는 방법 | |
KR950016724A (ko) | 폐경기 후 여성의 리비도를 증가시키는 방법 | |
KR950016735A (ko) | 터너 증후군의 억제 방법 | |
KR950016743A (ko) | 마이엘로퍼옥시다제 활성을 억제하는 방법 | |
KR950016742A (ko) | 폐경후 여성의 씨엔에스 질환을 억제하는 방법 | |
KR950016734A (ko) | 성적 조숙증의 억제방법 | |
KR950016729A (ko) | 유방 질환의 억제 방법 | |
KR950016733A (ko) | 난소 발육부전, 사춘기 지연, 또는 성적 유치증의 억제방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |